Showing 7091-7100 of 9461 results for "".
- REZOLVE-AD: Monthly and Quarterly Dosing of Rezpegaldesleukin Effective for ADhttps://practicaldermatology.com/news/rezolve-ad-monthly-and-quarterly-dosing-of-rezpegaldesleukin-effective-for-ad/2485647/Results from the blinded 36-week maintenance period showed rezpegaldesleukin demonstrated sustained disease control and new or deepening efficacy in moderate-to-severe atopic dermatitis (AD) with both monthly and quarterly dosing regimens, according to an announcem
- Analysis: Agent Orange Exposure Linked to Acral Melanoma Risk in US Veteranshttps://practicaldermatology.com/news/analysis-agent-orange-exposure-linked-to-acral-melanoma-risk-in-us-veterans/2485639/Acral melanoma (AM), a rare melanoma subtype, showed risk factor patterns in a large Veterans Affairs (VA)–based analysis spanning more than two decades, according to new data. In this case-control study of US veterans from 20
- Danish Registry Study Shows Rising cSCC and CIS Incidence Over 18 Yearshttps://practicaldermatology.com/news/nearly-two-decades-of-data-highlight-shifting-patterns-in-keratinocyte-neoplasms/2485635/Incidence rates of cutaneous squamous cell carcinoma (cSCC) and cSCC in situ (CIS) have continued to rise in Denmark over nearly two decades, while keratoacanthoma (KA) incidence has declined, according to a large population-based registry study.
- Reduced-Dose Tralokinumab Maintains Symptom Control for Up to 1 Year in Atopic Dermatitishttps://practicaldermatology.com/news/reduced-dose-tralokinumab-maintains-symptom-control-for-up-to-1-year-in-atopic-dermatitis/2485613/Adults with moderate-to-severe atopic dermatitis (AD) who achieved initial disease control with tralokinumab maintained improvements in symptoms and quality of life for up to 1 year following reduced dosing, according to a South Beach Symposium poster from April
- Aesthetic Sequelae of GLP-1 Receptor Agonists Highlighted in Clinical Reviewhttps://practicaldermatology.com/news/aesthetic-sequelae-of-glp-1-receptor-agonists-highlighted-in-clinical-review/2485615/Dermatologists are increasingly encountering aesthetic complications associated with GLP-1 receptor agonist (RA)–induced weight loss, according to a clinical review presented at the South Beach Symposium. The poster, b
- Nutrafol Launches Men 50+ Formula Targeting Age-Related Hair Thinninghttps://practicaldermatology.com/news/nutrafol-launches-men-50-formula-targeting-age-related-hair-thinning/2485568/Nutrafol announced an expansion of its men’s portfolio with the launch of Nutrafol Men 50+, a product designed specifically for men aged 50 years and older with thinning hair. According to the company, men entering their 50s ex
- Imagining a Better Future for Hidradenitis Suppurativahttps://practicaldermatology.com/news/imagining-a-better-future-for-hidradenitis-suppurativa/2485556/Hidradenitis suppurativa (HS) has long been misunderstood, underdiagnosed, and undertreated. However, at a recent panel discussion led by Vivian Shi, MD, at
- OX40‑Targeted Therapy Among Dr. Hensin Tsao’s Highlights at Maui Derm Hawaii 2026https://practicaldermatology.com/news/ox40targeted-therapy-among-dr-hensin-tsaos-highlights-at-maui-derm-hawaii-2026/2485510/A novel immune pathway that may redefine atopic dermatitis (AD) treatment paradigms was among the highlights presented by Hensin Tsao, MD, in his conference-opening presentation at Maui Derm Hawaii 2026. Melanoma immunotherapy and various other topics were covered, but perhaps the most pot
- Study: Mycophenolate Mofetil Effective as First-Line Option for Juvenile Localized Sclerodermahttps://practicaldermatology.com/news/study-mycophenolate-mofetil-effective-as-first-line-option-for-juvenile-localized-scleroderma/2485505/A new study comparing methotrexate (MTX) and mycophenolate mofetil (MMF) suggests MMF may offer a comparable alternative with better patient-reported tolerability outcomes. Researchers analyzed data from 114 patients (MTX [n=68
- Study Flags Gaps in Readability, Representation in Monkeypox and HIV Resourceshttps://practicaldermatology.com/news/study-flags-gaps-in-readability-representation-in-mpox-and-hiv-resources/2485494/A new study reports that critical information on monkeypox (Mpox) and HIV remains largely inaccessible to the general public due to high reading levels and inconsistent cultural representation. Researchers publishing in the <